KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biogen (BIIB) Operating Income (2016 - 2026)

Biogen has reported Operating Income over the past 18 years, most recently at -$283.3 million for Q1 2026.

  • For Q1 2026, Operating Income rose 10.94% year-over-year to -$283.3 million; the TTM value through Mar 2026 reached -$812.9 million, down 26.01%, while the annual FY2025 figure was -$847.7 million, 109.62% down from the prior year.
  • Operating Income for Q1 2026 was -$283.3 million at Biogen, up from -$551.5 million in the prior quarter.
  • Over five years, Operating Income peaked at $901.6 million in Q3 2022 and troughed at -$800.8 million in Q3 2023.
  • A 5-year average of $24.7 million and a median of -$77.4 million in 2024 define the central range for Operating Income.
  • On a YoY basis, Operating Income climbed as much as 76.56% in 2024 and fell as far as 328.84% in 2024.
  • Year by year, Operating Income stood at $439.8 million in 2022, then crashed by 70.99% to $127.6 million in 2023, then plummeted by 328.84% to -$292.0 million in 2024, then tumbled by 88.87% to -$551.5 million in 2025, then skyrocketed by 48.63% to -$283.3 million in 2026.
  • Business Quant data shows Operating Income for BIIB at -$283.3 million in Q1 2026, -$551.5 million in Q4 2025, and -$117.1 million in Q3 2025.